January 2011 NCIC CTG MA.20 (RTOG Endorsed) -1. Opened: December 14, 1999 Closed: February 2, 2007

Similar documents
NSABP PROTOCOL B-39 RTOG PROTOCOL 0413

S0819 Phase III. Coordinating Group: SWOG

APRIL 11-14, 2018 SWOG LYMPHOMA

Supplementary webappendix

January NCCTG Protocol No: N0927 Opened: September 3, 2009

Study No: Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Statistical Methods:

ADULT INTAKE FORM (13 and older) Name Date of First Visit Address City State Zip Code Telephone (home) (work) (cell) Is it ok to leave a message?

Supplementary Appendix

East West Acupuncture & Wellness Center, Inc. Patient Intake Form

Divine Medicine NW Greenbrier Parkway, Suite 100 Beaverton, Oregon P F

What are you seeking treatment for? Have you ever had acupuncture before? If so, for what condition?

H E A LT H H I S T O RY

Address: City: State: Zip: Age: Birth Date: Marital Status: M S W D No. of Children. Your Employer: Occupation: Years on Job:

NCCTG Status Report for Study N May 2010

CASE REPORT FORM (April 2012)

(PLEASE CIRCLE YES ANSWERS ONLY)

Holly Zapf, ND -- Whole Family Health Clinic

Adult Intake. (Please print clearly) Name Date. Address. Address. Home Telephone Number. Emergency contact: Name

The dher2 immunotherapeutic consists of recombinant dher2 protein combined with the GSK s proprietary immunostimulant AS15.

January NCCTG Protocol No: N0628 Opened: November 27, 2007 CALGB Protocol No: ECOG Protocol No: R0617

Premier Pain Consultants

Patient Intake Form. Name Date of birth Age Sex: Male Female

NAME: LAST FIRST MIDDLE INITIAL ADDRESS CITY STATE ZIP

Naturopathic Intake Paperwork

(Work address): How did you hear about our clinic? Has any other family member already been a patient at the clinic?

INTAKE FORM ADULT. Contact Information. Date

DR.CRISTINA COLOMA, ND 2888 GARDNER COURT ABBOTSFORD, BC V2T 5H9 Phone/Fax (604)

ADULT INTAKE. Name: Date: Address: City: Prov: PC: Telephone (home): (work): Age: Date of Birth: Gender: Female / Male

HEALTH HISTORY FORM. Patient Name: Birth Date: / / Supportive relationship(s)? Yes No Spiritual Practice? Yes No If yes,

Dr. Kevin Passero, N.D Lubrano Drive, Suite L 15, Annapolis, MD New Hampshire Ave Suite B4 NW Washington DC 20036

Non Prolotherapy Patient Intake Form

IMPROVING THE OUTCOMES OF BREAST RADIATION THERAPY: THE PRONE POSITION. Kaylyn Olson

Philip J Cimo DDS PA 650 West Bough Lane Ste #160 Houston TX

Portland Dental and Naturopathic Clinic

Yen Chiropractic, LLC Personal Injury Patient Intake Form Page 1

What is your stress level(1- none 10- very stressful) Occupational Personal

Date of Birth Gender. List, in order of importance, your goals for working with your physician:

SONG OF NATURAL MEDICINE Dr. Crystal Song, NMD

Family History. Patient Name: DOB: List in Order of importance what your health concerns are: 1) 2) 3) 4) 5)

Adult Intake - Prenatal

NCCTG Status Report for Study N May 2010

HISTORY AND PHYSICAL

Dr. Roxie Strand, NMD

LABETTE COMMUNITY COLLEGE BRIEF SYLLABUS. ANATOMY AND PHYSIOLOGY, lecture and lab

The following information is needed in order to better serve you. Please complete all questions.

Broken Arrow Public Schools Physiology Objectives

Charlotte, NC (980) Roanoke, VA (540)

Sioux Falls School District Anatomy and Physiology Holes Anatomy and Physiology Authors: Shier, Butler, and Lewis Glencoe/ McGraw hill

Srdan Verstovsek, MD, PhD Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center

Natural Healing Family Medicine

Chronic Granulomatous Disease Medical Management

c u l t i v a t e w e l l n e s s

Anatomy & Physiology Curriculum Map Date Content/Topics Objectives Activities/Assessments Aug. 7th- 21st

Adaptive Play and Wellness. Miela Gruber Cooley ND Registration Form (Please Print)

NEW PATIENT INTAKE. Name: Date: Address: Preferred Phone: ( ) Alternate Phone:( ) Leaving Voice Message OK: Y N Preferred method of contact:

SOUTH TEXAS BONE & JOINT

ANATOMY AND PHYSIOLOGY Revised 11/2010

Autologous Bone Marrow Transplant Crossword Puzzle on Discharge Education. Adult Bone Marrow Transplant Autologous Bone Marrow Transplant Puzzle 1

CHAPTER 3 HEART AND LUNG TRANSPLANTATION. Editors: Mr Mohamed Ezani Md. Taib Dato Dr David Chew Soon Ping Dr Ashari Yunus

Phone number: When and how did your pain begin? (a date is required for Medicare and some insurance policies) Date of onset:

Arizona Integrative Medical Solutions 4657 S. Lakeshore Dr, Ste #1 Tempe, AZ

1. Anatomy is. 2. Which subdivision of anatomy involves the study of organs that function together?

CARDIAC METASTASIS MASQUERADE AS STEMI D R S R E E K A N T H K O D U R

Integrative Medicine and Holistic Wellness Center 677 West Main Street Hyannis, MA 02601

Family members living at home with the patient: Patient s school: Emergency contact: Relationship: Phone:

CHAPTER 3 HEART AND LUNG TRANSPLANTATION. Editors: Mr Mohamed Ezani Md. Taib Dato Dr David Chew Soon Ping Dr Ashari Yunus

History of Present Illness

Chapter 1. The Human Organism 1-1

Heat and Cold in Medicine

Infant/Children Assessment sheet Medical- Surgical unit/ ICU

The influence of categorising survival time on parameter estimates in a Cox model

Supplementary Online Content

Supplemental Table 1 All Adverse Events Reported with Tolvaptan in North American & Japanese Subjects

Drug Analysis Print Drug name: RIMONABANT

Supplementary Material

Prepared by: The Center for Health Services and Outcomes Research

Initial Certification

Allogeneic Bone Marrow Transplant Crossword Puzzle on Discharge Education

12/1/17 OUTLINE KEY POINTS ELEMENTS WITH UNSTABLE NUCLEI Radioisotopes and Nuclear Reactions 16.2 Biological Effects of Nuclear Radiation

18. Which body system is needed for the exchange of oxygen and carbon dioxide? A. Respiratory B. Integumentary C. Digestive D. Urinary 19.

Practical APLIS-based Structured/Synoptic Reporting

Passaic County Technical Institute. Wayne, NJ. Anatomy and Physiology II Curriculum. August 2015

Clinical data successes using machine learning

Alternative Approaches to Thoracoscopic Lobectomy: Uniportal, Supxiphoid,

Everolimus e la ridefinizione del paradigma nel trattamento delle pazienti con carcinoma mammario ER+/HER2-

ESR1 Allele Frequency. PIK3CA Allele Frequency

Syllabus. BIO 172 Human Anatomy and Physiology II

Prepared by: The Center for Health Services and Outcomes Research

COURSE NAME: ENVIRONMENTAL STUDIES FOR UNDERGRADUATES FOR ALL COURSES PAPER TITLE: ENVIRONMENTAL STUDIES FOR UNDERGRADUATES

Introduction Chpt 1. Study Slides

GPS* Safety Summary for Hydrochloric Acid

Modesto Junior College Course Outline of Record ANAT 125

Chapter 22: Comparing two proportions. Religious identification Current at 16 Same Different Total Catholic Jewish

CHAPTER 9 BODY ORGANIZATION. Copyright 2007 by Mosby, Inc., an affiliate of Elsevier Inc. 1

Expand the probe idea functionality (above points) to larger imaging systems. First Applications, Probes, Isotopes

CURRICULUM MAP. TIME CONTENT PAGE REF. SKILLS ASSESSMENT/ACTIVITIES Day 1-3

CHAPTER 8. Editors: Dr Omar Sulaiman Dr Hooi Lai Seong

Grade Level: Physiology

AVICENNA INTERNATIONAL COLLEGE

Transcription:

January 2011 NCIC CTG MA.20 (RTOG Endorsed) -1 NCIC CTG MA.20 (RTOG Endorsed) Protocol Status: Opened: December 14, 1999 Closed: February 2, 2007 Title: A Phase III Study of Regional Radiation Therapy in Early Breast Cancer Patient Population: Pre or post-menopausal women with histologically confirmed node positive or high risk node negative invasive breast cancer with no evidence of distant metastases who have been treated by BCT and adjuvant chemotherapy and/or hormonal therapy and who are at high risk of regional and systematic recurrence. Objectives: To compare overall survival, disease-free survival, isolated local regional disease free survival, distant disease free survival, toxicity, quality of life and cosmetic outcome in women who have node positive or high risk node negative breast cancer treated with breast conserving therapy and who are randomized to receive standard breast radiation or breast radiation plus regional radiation. Schema: S T R A T I F Y 1. Number of positive nodes 2. Type of chemotherapy 3. Hormonal therapy 4. Number of axillary nodes removed 5. Centre R A N D O M I Z E Arm 1: Breast Radiation (Control) or Arm 2: Breast Radiation plus Regional Radiation () Coordinating Group: NCIC CTG Total patients entered: 1832 Participants: CTSU, NSABP, NCCTG, RTOG, TROG Study Chairs: Dr. Timothy Whelan (Chair) Dr. Ida Ackerman (Trial Committee) Dr. Julie Bowen (Trial Committee) Dr. Peter Craighead (Trial Committee) Dr. Mark Levine (Trial Committee) Dr. David McCready (Trial Committee) Dr. Abdenour Nabid (Trial Committee) Dr. Maureen Nolan (Trial Committee) Dr. Ivo Olivotto (Trial Committee) Dr. Kathleen Pritchard (Trial Committee) Dr. Katherine Vallis (Trial Committee) Dr. Carolyn Sartor (CALGB Co-Chair) Dr. Laura Vallow (NCCTG Co-Chair) Dr. David Parda (NSABP Co-Chair) Dr. Julia White (RTOG Co-Chair) Dr. Lori Pierce (SWOG Co-Chair) Dr. Boon Chua (TROG Co-Chair) Biostatistician: Physician Coordinator: Quality of Life Coordinator: Study Coordinator: Health Economics Coordinator: Dr. Judy-Anne Chapman Wendy Parulekar Dr. Timothy Whelan Yvonne Murray Douglas Coyle

January 2011 NCIC CTG MA.20 (RTOG Endorsed) -2 I. Summary: This NCIC CTG study opened on December 14, 1999 and closed on February 2, 2007 with a total of 1832 patients. Pretreatment characteristics can be found in Section III. Adverse event (AE) information can be found in Section IV. Adverse events were graded according to Common Toxicity Criteria Version 2.0 II. Administrative Information: Table 2.1 Patient Accrual Study sample size 1822 Total patients entered 1832 Average monthly accrual for the study 21.3 Table 2.2 Case Status Total patients entered 1832 Form 1 received 1831 Ineligible 20 Eligible 1811 Table 2.3 Cases Excluded (n=20) Reason Ineligible - High Risk Criteria Not Met 6 (30.0%) Ineligible - Axillary Dissection Not Done 3 (15.0%) Ineligible - Bilateral Mammogram >12 Months 3 (15.0%) Ineligible - Clinical T4 Prior to Surgery 2 (10.0%) Ineligible - Bilateral Mammogram Not Done 2 (10.0%) Ineligible - Serious Non-malignant Disease 1 (5.0%) Ineligible - Non-Invasive Disease 1 (5.0%) Ineligible - Malignant Disease 1 (5.0%) Ineligible - Prior RT for DCIS 1 (5.0%)

January 2011 NCIC CTG MA.20 (RTOG Endorsed) -3 III. Pretreatment Characteristics: Table 3.1 Pretreatment Characteristics (n=1811) TOTAL (n=902) (n=909) (n=1811) # % # % # % AGE AT ALLOCATION < 39 66 ( 7) 62 ( 7) 128 ( 7) 40-49 278 (31) 252 (28) 530 (29) 50-59 308 (34) 343 (38) 651 (36) 60-69 189 (21) 184 (20) 373 (21) > 70 61 ( 7) 68 ( 7) 129 ( 7) Median age (years) 52 53 53 PERFORMANCE STATUS (ECOG) 0 632 (70) 623 (69) 1255 (69) 1 262 (29) 273 (30) 535 (30) 2 8 ( 1) 13 ( 1) 21 ( 1) WEIGHT Unknown 3 ( 0) 1 ( 0) 4 ( 0) 40-59 kg 157 (17) 151 (17) 308 (17) 60-79 kg 474 (53) 463 (51) 937 (52) 80-99 kg 215 (24) 220 (24) 435 (24) 100-119 kg 40 ( 4) 53 ( 6) 93 ( 5) 120-139 kg 9 ( 1) 15 ( 2) 24 ( 1) 140 kg 4 ( 0) 6 ( 1) 10 ( 1) CHEMOTHERAPY No 84 ( 9) 85 ( 9) 169 ( 9) Yes 818 (91) 824 (91) 1642 (91) HORMONAL THERAPY No 405 (45) 403 (44) 808 (45) Yes 497 (55) 506 (56) 1003 (55) TYPE OF HORMONAL THERAPY Missing 16 ( 2) 17 ( 2) 33 ( 2) Arimidex 75 ( 8) 81 ( 9) 156 ( 9) Aromasin, Exemestane 6 ( 1) 3 ( 0) 9 ( 0) Femara, Letrozole 4 ( 0) 4 ( 0) 8 ( 0) Tamoxifen Citrate 394 (44) 399 (44) 793 (44) Unknown 2 ( 0) 2 ( 0) 4 ( 0)

January 2011 NCIC CTG MA.20 (RTOG Endorsed) -4 Table 3.1 Patient Characteristics TOTAL (n=902) (n=909) (n=1811) # % # % # % TYPE OF CHEMOTHERAPY anthracycline chemo 776 (86) 780 (86) 1556 (86) none (no chemo) 84 ( 9) 86 ( 9) 170 ( 9) other chemotherapy 42 ( 5) 43 ( 5) 85 ( 5) KNUCKLE CIRCUMFERENCE Affected Arm Mean (cm) 19.1 19.1 19.1 Unaffected Arm Mean (cm) 19.1 19.1 19.1 WRIST CIRCUMFERENCE Affected Arm Mean (cm) 16.3 16.3 16.3 Unaffected Arm Mean (cm) 16.2 16.3 16.3 DISTAL TO EPICONDYLE CIRCUMFERENCE Affected Arm Mean (cm) 24.1 24.3 24.2 Unaffected Arm Mean (cm) 24.0 24.3 24.2 PROXIMAL TO EPICONDYLE CIRCUMFERENCE Affected Arm Mean (cm) 30.9 31.4 31.2 Unaffected Arm Mean (cm) 30.7 31.3 31.0 Table 3.2 Additional Characteristics TOTAL (n=902) (n=909) (n=1811) # % # % # % LOCATION OF TUMOUR Left Side 430 (48) 438 (48) 868 (48) Right Side 472 (52) 471 (52) 943 (52) CARDIOVASCULAR DISEASE No 643 (71) 627 (69) 1270 (70) Unknown 1 ( 0) 0 ( 0) 1 ( 0) Yes 258 (29) 282 (31) 540 (30) MENOPAUSAL STATUS Post 496 (55) 532 (59) 1028 (57) Pre 406 (45) 377 (41) 783 (43) TNM STAGE T Stage 1 480 (53) 452 (50) 932 (51) 2 415 (46) 439 (48) 854 (47) 3 6 ( 1) 17 ( 2) 23 ( 1) N Stage 0 88 (10) 93 (10) 181 (10) 1 797 (88) 798 (88) 1595 (88) 2 15 ( 2) 15 ( 2) 30 ( 2) 3 1 ( 0) 2 ( 0) 3 ( 0) MARGINS Initially Clear 765 (85) 766 (84) 1531 (85) Focally Postive 136 (15) 142 (16) 278 (15) LESS THAN 1 mm CLEAR Missing 2 ( 0) 5 ( 1) 7 ( 0) No 599 (66) 585 (64) 1184 (65) Unknown 203 (23) 211 (23) 414 (23) Yes 98 (11) 108 (12) 206 (11) Clear Margin Mean(mm) 4.9 5.5 5.2

January 2011 NCIC CTG MA.20 (RTOG Endorsed) -5 Table 3.2 Additional Characteristics (n=902) (n=909) TOTAL (n=1811) BOOST WILL BE GIVEN # % # % # % Missing 2 ( 0) 2 ( 0) 4 ( 0) No 687 (76) 704 (77) 1391 (77) Yes 213 (24) 203 (22) 416 (23) LYMPHOVASCULAR INVASION Absent 485 (54) 502 (55) 987 (55) Present 372 (41) 373 (41) 745 (41) Unknown 44 ( 5) 33 ( 4) 77 ( 4) EXTENSIVE DCIS Absent 725 (80) 751 (83) 1476 (82) Present 116 (13) 100 (11) 216 (12) Unknown 60 ( 7) 57 ( 6) 117 ( 6) SBR GRADE Missing 1 ( 0) 2 ( 1) 3 ( 0) I 155 (17) 166 (18) 321 (18) II 360 (40) 348 (38) 708 (39) III 380 (42) 387 (43) 767 (42) U 6 ( 1) 6 ( 1) 12 ( 1) SENTINEL NODE BIOPSY PERFORMED No 551 (61) 552 (61) 1103 (61) Yes 350 (39) 356 (39) 706 (39) LYMPH NODES STATUS Mean Number Removed 12.3 12.4 12.4 Mean Number of Positive Nodes 1.6 1.7 1.6 NODAL STATUS Node Negative 85 ( 9) 87 (10) 172 ( 9) Node Positive 1-3 NODES 770 (85) 772 (85) 1542 (85) Node Positive > NODES 47 ( 5) 50 ( 6) 97 ( 5) ER STATUS Negative 232 (26) 228 (25) 460 (25) Positive 670 (74) 681 (75) 1351 (75) BIOCHEMICAL MEAN ER (fmol/mg protein) 80.2 81.8 80.9 PR STATUS Negative 364 (40) 358 (39) 722 (40) Not Applicable/Not Done 2 ( 0) 3 ( 0) 5 ( 0) Positive 536 (59) 548 (60) 1084 (60) BIOCHEMICAL MEAN PR (fmol/mg protein) 99.8 175.5 137.2 HER2 NEU TESTING No 332 (37) 324 (36) 656 (36) Yes 569 (63) 584 (64) 1153 (64) HER2 NEU TESTING RESULTS 0 or 1 + 458 (51) 476 (52) 934 (52) 2+ 28 ( 3) 43 ( 5) 71 ( 4) 3+ 73 ( 8) 62 ( 7) 135 ( 7) 5 7 ( 1) 1 ( 0) 8 ( 0) Unknown 3 ( 0) 2 ( 0) 5 ( 0) NA 332 (37) 324 (36) 656 (36) EORTC QLQ - C30 WITHIN 14 DAYS PRIOR TO RADn No 97 (11) 102 (11) 199 (11) Yes 805 (89) 807 (89) 1612 (89) EORTC CRS WITHIN 14 DAYS PRIOR TO RADn No 30 ( 3) 31 ( 3) 61 ( 3) Yes 872 (97) 878 (97) 1750 (97)

January 2011 NCIC CTG MA.20 (RTOG Endorsed) -6 IV. Toxicities: Table 4.1 Baseline Toxicity Evaluable patients 902 Evaluable patients - 909 ALLERGY Allergic rhinitis 7 3 10 (1) (0) 12 2 14 (2) (0) Allergic reaction 1 1 (0) (0) 1 1 (0) (0) AUDITORY Inner ear/hearing 1 2 3 (0) (0) 2 1 3 (0) (0) Middle ear/hearing 1 1 2 (0) (0) BLOOD/BONE MARROW Hemolysis 1 1 (0) (0) CARDIOVASCULAR Other Arrhythmia 1 1 (0) (0) Edema 11 2 13 (1) (0) 10 1 11 (1) (0) Cardiac LVF 2 2 (0) (0) 1 1 2 (0) (0) Hypertension 1 1 1 3 (0) (0) 1 1 (0) (0) Ischemia/infarction 1 1 (0) (0) Palpitations 2 2 (0) (0) 1 1 (0) (0) Phlebitis 1 1 (0) (0) Supraventric. arrhyth. 1 1 (0) (0) Thrombosis/embolism 2 2 (0) (0) ENDOCRINE Hot flashes/flushes 34 70 104 (12) (0) 32 46 78 (9) (0) Gynecomastia 96 16 112 (12) (0) 70 18 88 (10) (0) Hypothyroidism 6 3 9 (1) (0) 1 3 4 (0) (0) FLU-LIKE SYMPTOMS Fever 1 1 (0) (0) 2 2 (0) (0) Fatigue 447 125 8 580 (64) (0) 441 122 6 569 63) (0) Rigors, chills 1 1 (0) (0) 2 2 (0) (0) Sweating 1 3 4 (0) (0) 5 2 7 (1) (0) GASTROINTESTINAL Anorexia 18 1 19 (2) (0) 19 1 20 (2) (0) Ascites 1 1 (0) (0) Colitis 1 1 (0) (0) 1 1 (0) (0) Constipation 19 5 24 (3) (0) 27 11 38 (4) (0) Dehydration 1 1 (0) (0) Diarrhea 11 3 14 (2) (0) 9 2 1 12 (1) (0) Dysphagia 5 5 (1) (0) 4 4 (0) (0) Mouth dryness 3 3 (0) (0) 5 5 (1) (0) Flatulence 1 1 (0) (0) 3 2 5 (1) (0) Dyspepsia/heartburn 20 3 23 (3) (0) 18 3 21 (2) (0) Nausea 38 2 40 (4) (0) 43 4 47 (5) (0) Proctitis 3 3 (0) (0) 1 1 (0) (0) Salivary gland changes 2 2 (0) (0) Sense of smell 1 1 (0) (0) 2 2 (0) (0) Stomatitis 8 3 11 (1) (0) 10 6 16 (2) (0) Taste disturbance 16 8 24 (3) (0) 19 2 21 (2) (0) Vomiting 3 1 4 (0) (0) 6 6 (1) (0) RENAL Urine frequency/urgency 6 1 7 (1) (0) 3 3 (0) (0) Incontinence 2 2 (0) (0) 2 2 (0) (0) Renal failure 1 1 (0) (0) Dysuria 2 2 (0) (0) 1 1 (0) (0) Bladder spasms 1 1 (0) (0) Vaginitis 1 1 (0) (0) 1 1 (0) (0) HEMORRHAGE Epistaxis 1 1 (0) (0) Rectal bleeding 1 1 (0) (0) Vaginal bleeding 1 1 2 (0) (0) 1 1 (0) (0) HEPATIC

January 2011 NCIC CTG MA.20 (RTOG Endorsed) -7 Table 4.1 Baseline Toxicity Evaluable patients 902 Evaluable patients - 909 INFECTION Infection w/o neutropenia 3 4 7 (1) (0) 4 4 8 (1) (0) Febrile neutropenia 1 1 (0) (0) LYMPHATICS Lymphedema 57 2 59 (7) (0) 51 5 56 (6) (0) MUSCULOSKELETAL Osteonecrosis 1 1 (0) (0) Arthritis 7 5 12 (1) (0) 17 4 21 (2) (0) Muscle weakness 96 10 1 107 (12) (0) 91 12 2 105 (12) (0) Other 1 2 3 (0) (0) METABOLIC Hypercholesterolemia 1 1 (0) (0) Hyperglycemia 1 1 (0) (0) NEUROLOGY Anxiety 16 1 17 (2) (0) 7 2 9 (1) (0) Ataxia 1 1 (0) (0) Cognitive disturbance 1 1 (0) (0) 1 1 (0) (0) Dizziness 4 1 5 (1) (0) 4 1 1 6 (1) (0) Euphoria 1 1 (0) (0) Insomnia 18 16 2 36 (4) (0) 17 6 3 26 (3) (0) Memory loss 5 1 6 (1) (0) 2 2 (0) (0) Depression 13 5 18 (2) (0) 6 7 13 (1) (0) Neuropathy-motor 19 3 1 23 (3) (0) 17 4 1 22 (2) (0) Neuropathy-sensory 319 18 3 1 341 (38) (0) 332 21 2 355 (39) (0) Seizure(s) 1 1 (0) (0) Depressed conscious 1 1 (0) (0) Tremor 2 2 (0) (0) Vertigo 1 1 (0) (0) OCULAR Blurred vision 4 4 (0) (0) 7 7 (1) (0) Cataract 1 1 2 (0) (0) 1 1 (0) (0) Conjunctivitis 1 1 (0) (0) Dry eye 1 2 3 (0) (0) Glaucoma 1 1 2 (0) (0) Keratitis 1 1 (0) (0) Tearing 9 9 (1) (0) 11 1 12 (1) (0) Other 6 6 (1) (0) 1 1 (0) (0) PAIN Chest pain 6 6 (1) (0) 2 1 3 (0) (0) Abdominal pain 4 4 (0) (0) 2 1 3 (0) (0) Headache 11 9 20 (2) (0) 9 5 1 15 (2) (0) Arthralgia 26 12 1 39 (4) (0) 36 15 51 (6) (0) Myalgia 135 24 2 161 (18) (0) 141 20 2 163 (18) (0) Neuropathic pain 58 11 3 72 (8) (0) 41 6 47 (5) (0) Bone pain 6 3 1 10 (1) (0) 5 1 6 (1) (0) Pain-Other 13 5 18 (2) (0) 10 1 11 (1) (0) Pleuritic pain 7 2 9 (1) (0) 9 1 10 (1) (0) Rectal/perirectal pain 2 2 (0) (0) 2 2 (0) (0) PULMONARY Cough 137 4 141 (16) (0) 133 4 137 (15) (0) Pulmonary fibrosis 1 1 (0) (0) Pneumonitis 2 2 (0) (0) Dyspnea 190 1 191 (21) (0) 1 184 1 186 (20) (0) Voice changes 1 1 (0) (0) DERMATOLOGY Alopecia 24 126 150 (17) (0) 14 149 163 (18) (0) Bruising 1 1 (0) (0) Dry skin 3 3 6 (1) (0) 4 1 5 (1) (0) Flushing 1 1 (0) (0) Wound-infections 1 1 2 (0) (0)

January 2011 NCIC CTG MA.20 (RTOG Endorsed) -8 Table 4.1 Baseline Toxicity Evaluable patients 902 Evaluable patients - 909 DERMATOLOGY Injection site reaction 2 1 3 (0) (0) Nail changes 11 7 18 (2) (0) 7 3 10 (1) (0) Wound-non-infectious 1 1 2 (0) (0) Pigmentation changes 5 5 (1) (0) 4 4 (0) (0) Pruritus 1 1 (0) (0) Rash/desquamation 13 3 1 17 (2) (0) 15 1 16 (2) (0) Erythema multiforme 2 2 (0) (0) Urticaria 1 1 (0) (0) 1 1 (0) (0) 1 1 (0) (0) SEXUAL/REPRODUCTIVE Irregular menses 2 7 21 30 (3) (0) 1 6 16 23 (3) (0) Vaginal dryness 3 1 4 (0) (0) 1 2 3 (0) (0) WEIGHT Weight gain 1 1 2 (0) (0) Weight loss 1 1 (0) (0) 1 1 2 (0) (0) WORST OVERALL GRADE 333 386 45 1 765 (85) (0) 345 376 38 759 (83) (0) Table 4.2 Acute Adverse Events Evaluable patients 895 Evaluable patients - 904 ALLERGY Allergic rhinitis 2 2 2 (0) (0) 4 1 5 (0) (0) AUDITORY Inner ear/hearing 1 1 (0) (0) BLOOD/BONE MARROW Leukocytes (total WBC) 1 1 (0) (0) CARDIOVASCULAR Edema 5 1 6 (1) (0) 2 2 (0) (0) Cardiac LVF 1 1 (0) (0) Ischemia/infarction 1 1 (0) (0) Palpitations 2 2 (0) (0) 1 1 (0) (0) Pericardial effusion 1 1 (0) (0) 1 1 (0) (0) Sinus tachycardia 2 2 (0) (0) Cardiac troponin I 1 1 (0) (0) Vasovagal episode 1 1 (0) (0) Thrombosis/embolism 1 1 (0) (0) ENDOCRINE Hot flashes/ flushes 22 38 60 (7) (1) 13 23 36 (4) (0) Gynecomastia 230 27 1 258 (29) (28) 225 38 1 264 (29) (29) Masculiniz'n of female 1 1 (0) (0) Hypothyroidism 1 1 (0) (0) FLU-LIKE SYMPTOMS Fever 2 1 3 (0) (0) Fatigue 417 127 10 554 (62) (60) 418 134 10 562 62) (60) Rigors, chills 3 3 (0) (0) Sweating 3 3 (0) (0) 1 1 (0) (0)

January 2011 NCIC CTG MA.20 (RTOG Endorsed) -9 Table 4.2 Acute Adverse Events Evaluable patients 895 Evaluable patients - 904 GASTROINTESTINAL Anorexia 7 2 9 (1) (0) 9 1 10 (1) (1) Colitis 1 1 (0) (0) Constipation 7 1 8 (1) (0) 3 1 4 (0) (0) Diarrhea 4 4 (0) (0) 3 3 (0) (0) Dysphagia 3 3 (0) (0) Mouth 2 2 (0) (0) 1 1 (0) (0) Dyspepsia/heartburn 6 6 (1) 0) 1 2 3 (0) (0) Nausea 14 4 18 (2) (1) 23 2 25 (3) (2) Proctitis 1 1 (0) (0) Dysphagia-RT esophageal 2 1 3 (0) (0) Mucositis c/o radiation 1 1 (0) (0) Dysphagia-RT pharyngeal 3 3 (0) (0) Stomatitis 1 1 2 (0) (0) 3 3 (0) (0) Taste disturbance 2 2 4 (0) (0) 4 4 (0) (0) Vomiting 3 3 (0) (0) 1 2 3 (0) (0) RENAL Urine frequency/urgency 1 1 (0) (0) 1 1 (0) (0) Vaginitis 5 5 (1) (0)) 2 2 (0) (0) HEMORRHAGE Rectal bleeding 1 1 (0) (0) Petechiae/purpura 1 1 (0) (0) INFECTION Infection w/o neutropenia 3 3 (0) (0) 1 1 (0) (0) LYMPHATICS Lymphedema 41 4 45 (5) (4) 47 5 52 (6) (6) MUSCULOSKELETAL Arthritis 7 1 8 (1) (0) 7 7 (1) (0) Muscle 61 13 74 (8) (6) 85 5 90 (10) (8) Myositis 1 1 (0) (0) NEUROLOGY Anxiety 4 1 5 (1) (0) 1 2 3 (0) (0) Ataxia 1 1 (0) (0) Dizziness 1 1 (0) (0) 3 3 (0) (0) Euphoria 1 1 (0) (0) Insomnia 8 5 13 (1) (0) 4 3 3 10 (1) (0) Memory 1 1 (0) (0) 1 1 (0) (0) Depression 2 2 4 (0) (0) 3 2 5 (1) (0) Neuropathy-motor 5 1 6 (1) (0) 6 3 9 (1) (1) Personality/behavioral 1 1 (0) (0) Neuropathy-sensory 131 4 135 (15) (6) 146 5 151 (17) (8) Seizure(s) 1 1 (0) (0) Tremor 1 1 (0) (0) Vertigo 1 1 (0) (0) OCULAR Tearing 1 1 (0) (0) 1 1 (0) (0) Double vision 1 1 (0) (0) PAIN Earache 1 1 (0) (0) Chest 1 1 (0) (0) 1 2 3 (0) (0) Abdominal 2 2 (0) (0) 1 1 1 3 (0) (0) Headache 6 2 1 9 (1) (0) 6 1 7 (1) (0) Arthralgia 19 6 2 27 (3) (1) 15 4 19 (2) (0) Myalgia 102 18 120 (13) (10) 116 12 1 129 (14) (12) Neuropathic 35 1 1 37 (4) (4) 35 5 1 41 (5) (4) Bone 6 6 (1) (0) 6 6 (1) (0) Pain-Other 2 2 (0) (0) 2 2 (0) (0) Pleuritic 8 1 9 (1) (1) 7 3 1 11 (1) (1) Rectal/perirectal 1 1 (0) (0) Pain 149 23 3 175 (20) (20) 159 34 5 198 (22) (22)

January 2011 NCIC CTG MA.20 (RTOG Endorsed) -10 Table 4.2 Acute Adverse Events Evaluable patients 895 Evaluable patients - 904 PULMONARY Cough 107 2 1 110 (12) (8) 120 1 121 (13) (10) Pleural effusion 1 1 (0) (0) Hiccoughs 1 1 (0) (0) Pneumonitis 1 1 2 (0) (0) 3 3 (0) (0) Dyspnea 101 1 102 (11) (6) 107 2 109 (12) (8) Voice changes 1 1 (0) (0) 2 2 (0) (0) LATE RT MORBIDITY SCORING Joint 8 4 12 (1) (1) 9 2 11 (1) (1) Skin 2 2 (0) (0) 5 5 (1) (1) DERMATOLOGY Alopecia 8 14 22 (2) (0) 7 15 22 (2) (0) Bruising 1 1 (0) (0) Dry skin 4 4 (0) (0) 3 1 4 (0) (0) Nail changes 3 1 4 (0) (0) 2 2 (0) (0) Wound-non-infectious 1 1 (0) (0) 1 1 (0) (0) Pigmentation changes 19 2 21 (2) (2) 18 2 20 (2) (2) Pruritus 22 2 24 (3) (3) 26 6 32 (4) (3) Radiation dermatitis 457 326 19 802 (90) (90) 405 383 46 834 (92) (92) Rash/desquamation 4 7 11 (1) (1) 10 6 16 (2) (1) Other 1 1 2 (0) (0) 2 1 3 (0) (0) SEXUAL/REPRODUCTIVE Irregular menses 1 3 4 (0) (0) 2 2 (0) (0) Vaginal dryness 1 1 2 (0) (0) 2 2 (0) (0) Libido 1 1 (0) (0) WEIGHT Weight gain 1 1 (0) (0) Weight loss 1 1 (0) (0) WORST OVERALL GRADE 373 452 39 864 (97) (96) 312 500 68 880 (97) (97) Table 4.3 Delayed Adverse Events Evaluable patients 896 Evaluable patients - 900 ALLERGY Allergic rhinitis 1 1 (0) (0) 6 6 (1) (0) Auto-immune reaction 1 1 (0) (0) AUDITORY Inner ear/hearing 1 1 2 (0) (0) 2 2 (0) (0) BLOOD/BONE MARROW Hemoglobin 1 1 (0) (0) SECONDARY MALIGNANCY Secondary Malignancy 1 1 (0) (0) 2 2 (0) (0) CARDIOVASCULAR Edema 16 4 20 (2) 0) 7 7 (1) (0) Cardiac LVF 2 1 1 4 (0) (0) 4 4 8 (1) (1) Hypertension 1 1 (0) (0) 1 1 (0) (0) Ischemia/infarction 2 1 3 (0) (0) 2 2 (0) (0)

January 2011 NCIC CTG MA.20 (RTOG Endorsed) -11 Table 4.3 Delayed Adverse Events Evaluable patients 896 Evaluable patients - 900 Pericardial effusion 1 1 2 (0) (0) Supraventric. arrhyth. 1 1 (0) (0) ENDOCRINE Cushingoid appearance 1 1 (0) (0) Hot flashes/flushes 37 54 91 (10) (2) 26 49 75 (8) (2) Gynecomastia 321 61 2 384 (43) (42) 323 66 2 391 (43) (43) Masculiniz'n of female 2 2 (0) (0) 2 2 (0) (0) Hypothyroidism 2 2 (0) (0) 1 1 2 (0) (0) FLU-LIKE SYMPTOMS Fever 1 1 (0) (0) 1 1 (0) (0) Fatigue 356 101 8 465 (52) (48) 388 96 16 500 (56) (50) Rigors, chills 1 1 (0) (0) Sweating 1 2 3 (0) (0) 4 2 6 (1) (0) GASTROINTESTINAL Anorexia 3 2 5 (1) (0) 4 4 (0) (0) Colitis 1 1 (0) (0) Constipation 4 2 6 (1) (0) 4 4 8 (1) (0) Dehydration 1 1 (0) (0) Diarrhea 3 2 1 6 (1) (0) 2 1 3 (0) (0) Dysphagia 3 1 4 (0) (0) Mouth dryness 2 2 (0) (0) 3 4 (0) (0) Dyspepsia/heartburn 5 2 7 (1) (0) 6 2 1 9 (1) (1) Nausea 12 2 1 15 (2) (1) 8 1 9 (1) (1) Proctitis 1 1 (0) (0) Dysphagia-RT esophageal 1 1 (0) (0) 2 2 (0) (0) Mucositis radiation c/o radiation 1 1 (0) (0) Dysphagia-RT pharyngeal 2 2 (0) (0) Sense of smell 1 1 2 (0) (0) 1 1 (0) (0) Stomatitis 1 1 (0) (0) 1 1 (0) (0) Taste disturbance 5 1 6 (1) (0) 1 1 (0) (0) Vomiting 1 2 1 4 (0) (0) 1 1 (0) (0) RENAL Incontinence 1 1 (0) (0) Vaginitis 6 2 8 (1) (0) 8 8 (1) (0) HEMORRHAGE Melena/GI bleeding 1 1 (0) (0) Rectal bleeding 1 1 (0) (0) Vaginal bleeding 1 2 3 (0) (0) 1 1 (0) (0) INFECTION Infection w/o neutropenia 3 4 1 8 (1) (0) 2 3 5 (1) (0) Infection-unknown ANC 1 1 (0) (0) LYMPHATICS Lymphedema 149 37 2 1 190 (21) (21) 166 66 4 236 (26) (26) MUSCULOSKELETAL Osteonecrosis 1 1 2 (0) (0) Arthritis 13 2 15 (2) (0) 11 2 2 15 (2) (0) Muscle weakness 140 15 3 158 (18) (15) 169 124 4 197 (22) (20) Other 2 2 (0) (0) 2 1 3 (0) (0) METABOLIC Hypercholesterolemia 1 1 (0) (0) NEUROLOGY Anxiety 1 1 2 (0) (0) 1 1 2 (0) (0) CNS cerebrovasc ischem 1 1 (0) (0) Confusion 1 1 (0) (0) Dizziness 3 1 4 (0) (0) 4 4 ((0) (0) Insomnia 9 3 2 14 (2) (0) 7 12 1 20 (2) (0) Memory loss 2 1 3 (0) (0) Depression 3 7 1 11 (1) (0) 4 3 7 (1) (0) Neuropathy-motor 14 1 15 (2) (0) 25 8 1 34 (4) (3) Neuropathy-sensory 213 14 1 228 (25) (18) 243 19 4 266 (30) (23) Vertigo 2 2 (0) (0)

January 2011 NCIC CTG MA.20 (RTOG Endorsed) -12 Table 4.3 Delayed Adverse Events Evaluable patients 896 Evaluable patients - 900 OCULAR Blurred vision 2 2 (0) (0) Cataract 1 1 2 (0) (0) Dry eye 1 1 (0) (0) Tearing 1 1 (0) (0) 1 1 (0) ( 0) PAIN Tumor pain 1 Chest pain 4 4 (0) (0) 1 1 (0) (0) Abdominal pain 1 1 (0) (0) 4 4 (0) (0) Dysmenorrhea 1 1 (0) (0) Headache 7 2 1 10 (1) (0) 8 3 1 12 (1) (0) Arthralgia 21 17 1 39 (4) (1) 23 11 1 35 (4) (1) Myalgia 193 32 5 1 231 (26) (21) 232 52 4 288 (32) (29) Neuropathic pain 117 4 4 125 (14) (12) 89 17 1 107 (12) (10) Bone pain 7 3 1 11 (1) (1) 8 2 10 (1) (0) Pain-Other 3 2 5 (1) (0) 3 2 (0) (0) Pelvic pain 1 1 (0) (0) 1 1 (0) (0) Pleuritic pain 28 3 31 (3) ( 3) 26 5 1 32 (4) ( 3) Pain due to radiation 227 40 3 270 (30) (30) 218 47 6 271 (30) (30) PULMONARY Cough 114 10 124 (14) (9) 133 14 1 148 (16) (13) Pleural effusion 1 1 (0) (0) Pulmonary fibrosis 5 5 (1) (1) 23 4 27 (3) (3) Pneumonitis 5 2 1 8 (1) (1) 12 12 24 (3) (3) Dyspnea 152 1 153 (17) (12) 170 12 182 (20) (16) Voice changes 2 2 (0) (0) Other 2 2 (0) (0) LATE RT MORBIDITY SCORING Heart 1 1 (0) (0) Joint 68 11 1 80 (9) (9) 68 22 90 (10) (10) Lung 2 1 3 (0) (0) 9 1 1 11 (1) (1) Bone 1 1 2 (0) (0) Skin 265 32 1 298 (33) (33) 261 43 4 308 (34) (34) Subcutaneous tissue 150 14 164 (18) (18) 143 27 2 172 (19) (19) DERMATOLOGY Alopecia 5 4 9 (1) (0) 3 5 8 (1) (0) Bruising 2 2 (0) (0) 1 1 2 (0) (0) Dry skin 8 8 (1) (1) 15 1 16 (2) (2) Flushing 1 1 (0) (0) Wound-infectious 2 3 2 7 (1) (0) 2 4 6 (1) (1) Injection site reaction 1 1 (0) (0) 1 1 (0) (0) Nail changes 1 1 2 (0) (0) Wound-non-infectious 2 2 (0) (0) 2 1 3 (0) (0) Photo-sensitivity 1 1 (0) (0) 1 1 (0) (0) Pigmentation changes 102 4 106 (12) (11) 96 6 102 (11) (11) Pruritus 8 1 9 (1) (1) 16 2 18 (2) (2) Radiation dermatitis 263 55 3 321 (36) (35) 272 66 10 348 (39) (39) Rash/desquamation 6 4 10 (1) (1) 6 6 12 (1) (1) Other 32 3 1 36 (4) (4) 28 28 (3) (3) SEXUAL/REPRODUCTIVE Irregular menses 7 7 (1) (0) 7 7 (1) (0) Vaginal dryness 1 2 3 (0) (0) 4 1 5 (1) (0) Libido 1 1 (0) (0) 2 2 (0) (0) WEIGHT Weight gain 2 1 3 (0) (0) 6 2 8 (1) (0) Weight loss 1 4 5 (1) (0) 1 1 2 (0) (0) WORST OVERALL GRADE 393 363 44 1 1 802 (90) (89) 382 371 78 4 835 (93) (92)

2024 © sciencedocbox.com Privacy Policy | Terms of Service | Feedback